It’s easy to order labs—it’s the interpretation that’s difficult. In this article, we’ll review some of the more common labs you are likely to order as psychiatrists and give you some tips on interpreting them, as well as discussing what (if anything) you should do when a lab is abnormal.
Read More
Having a heart attack is depressing. Systematic reviews have found that depression increases the risk of future development of heart disease by 64% (Wulsin et al., Psychsom Med 2003;65: 201-210). But what do these facts mean in the terms of treatment?
Read More
Dr. Yohanan, as an internist specializing in geriatric medicine, you see many patients with “metabolic syndrome.” But there is a great deal of confusion out there as to what metabolic syndrome actually is, and whether that term remains useful.
Read More
Over the past several months, we have reviewed several articles that have endorsed cognitive behavioral therapy for the treatment of depression. In some cases, CBT has appeared even more effective than antidepressants, at least for the long-term prevention of relapse. But now, along comes a paper that appears to show that CBT isn’t particularly effective after all.
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
KarXT (Cobenfy) is the first antipsychotic that doesn’t block dopamine. We trace the origins of this new drug to a South Asian herb used for over 5,000 years, up to the three...